Company Profile

ImmuCell Corporation
Profile last edited on: 6/9/2024      CAGE: -----      UEI: ----------

Business Identifier: Protective antibody developer: milk-derived passive antibodies
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

56 Evergreen Drive
Portland, ME 04103
   (207) 878-2770
Location: Single
Congr. District: 01
County: Cumberland

Public Profile

ImmuCell Corporation, a biotechnology company organized around improving animal health and productivity in the dairy and beef industries. The Company has developed products that provide immediate immunity to newborn dairy and to beef cattle with product line extensions of its existing products that address mastitis. The Company's lead product, First Defense, is manufactured from cows' colostrum utilizing its vaccine and milk protein purification technologies. Its Wipe Out Dairy Wipes are made from a non-woven fabric that allows for a vigorous cleaning. Also developed is California Mastitis Test (CMT), which is used for bulk tank, as well as individual cow sample monitoring and is used to determine which quarter of the udder is mastitic. The firm also offers Rapid Johne’s Test enabling identification of the cattle with symptomatic Johne’s disease in a herd. Products are available to dairy producers, bovine veterinarians, and veterinary laboratories directly, as well as through veterinarian distributors.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2002 1 NIH $191,083
Project Title: Jenseniin P and Nisin to treat topical infections
2001 1 USDA $70,000
Project Title: A Novel Dry Cow Therapy
2001 1 USDA $70,000
Project Title: Immunomagnetic Separation Assay for Mycobacterium paratuberculosis
2001 1 NIH $196,247
Project Title: Novel Antimicrobial Treatment For Mastitis
1998 2 NIH $810,202
Project Title: Travelers Diarrhea and E Coli--Prevalence of Pilus AGS

Key People / Management

  Michael F Brigham -- President

  Richard T Coughlin

  Joseph H Crabb -- Chief Scientific Officer and Vice P.

  Daniel Freedman

  Samuel A Lewis

Company News

There are no news available.